Spatially Resolved PAH Emission Features in Nearby, Low Metallicity, Star-Forming Galaxies

Low-resolution, mid-infrared Spitzer/IRS spectral maps are presented for three nearby, low-metallicity dwarf galaxies (NGC 55, NGC 3109 and IC 5152) for the purpose of examining the spatial distribution and variation of polycyclic aromatic hydrocarbon (PAH) emission. The sample straddles a metallicity of 12+log(O/H)~8.0, a transition point below which PAH intensity empirically drops and the character of the interstellar medium changes. We derive quantitative radiances of PAH features and atomic lines on both global and spatially-resolved scales. The Spitzer spectra, combined with extensive ancillary data from the UV through the mid-infrared, allow us to examine changes in the physical environments and in PAH feature radiances down to a physical scale of 50 pc. We discuss correlations between various PAH emission feature and atomic line radiances. The (6.2 micron)/(11.3 micron), (7.7 micron)/(11.3 micron), (8.6 micron)/(11.3 micron), (7.7 micron)/(6.2 micron), and (8.6 micron)/(6.2 micron) PAH radiance ratios are found to be independent of position across all three galaxies, although the ratios do vary from galaxy to galaxy. As seen in other galaxies, we find no variation in the grain size distribution as a function of local radiation field strength. Absolute PAH feature intensities as measured by a ratio of PAH/(24 micron) radiances are seen to vary both positionally within a given galaxy, and from one galaxy to another when integrated over the full observed extent of each system. We examine direct comparisons of CC mode PAH ratios (7.7 micron)/(6.2 micron) and (8.6 micron)/(6.2 micron) to the mixed (CC/CH) mode PAH ratio (7.7 micron)/(11.3 micron). We find little variation in either mode, and no difference in trends between modes. While the local conditions change markedly over the observed regions of these galaxies, the properties of PAH emission show a remarkable degree of uniformity.Comment: Astrophysical Journal, in pres

Discovery of a Gas-Rich Companion to the Extremely Metal-Poor Galaxy DDO 68

We present HI spectral-line imaging of the extremely metal-poor galaxy DDO 68. This system has a nebular oxygen abundance of only 3% Z$_{\odot}$, making it one of the most metal-deficient galaxies known in the local volume. Surprisingly, DDO 68 is a relatively massive and luminous galaxy for its metal content, making it a significant outlier in the mass-metallicity and luminosity-metallicity relationships. The origin of such a low oxygen abundance in DDO 68 presents a challenge for models of the chemical evolution of galaxies. One possible solution to this problem is the infall of pristine neutral gas, potentially initiated during a gravitational interaction. Using archival HI spectral-line imaging obtained with the Karl G. Jansky Very Large Array, we have discovered a previously unknown companion of DDO 68. This low-mass (M$_{\rm HI}$ $=$ 2.8$\times$10$^{7}$ M$_{\odot}$), recently star-forming (SFR$_{\rm FUV}$ $=$ 1.4$\times$10$^{-3}$ M$_{\odot}$ yr$^{-1}$, SFR$_{\rm H\alpha}$ $<$ 7$\times$10$^{-5}$ M$_{\odot}$ yr$^{-1}$) companion has the same systemic velocity as DDO 68 (V$_{\rm sys}$ $=$ 506 km s$^{-1}$; D $=$ 12.74$\pm$0.27 Mpc) and is located at a projected distance of 42 kpc. New HI maps obtained with the 100m Robert C. Byrd Green Bank Telescope provide evidence that DDO 68 and this companion are gravitationally interacting at the present time. Low surface brightness HI gas forms a bridge between these objects.Comment: Accepted for publication in the Astrophysical Journal Letter

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam

Background The aim of this study was to evaluate the predictive performance of the INCREMENT-CPE (ICS), Pitt bacteremia score (PBS) and qPitt for mortality among patients treated with ceftazidime–avibactam for carbapenem-resistant Enterobacteriaceae (CRE) infections. Methods Retrospective, multicenter, cohort study of patients with CRE infections treated with ceftazidime–avibactam between 2015 and 2019. The primary outcome was 30-day all-cause mortality. Predictive performance was determined by assessing discrimination, calibration and precision. Results In total, 109 patients were included. Thirty-day mortality occurred in 18 (16.5%) patients. There were no significant differences in discrimination of the three scores [area under the curve (AUC) ICS 0.7039, 95% CI 0.5848–0.8230, PBS 0.6893, 95% CI 0.5709–0.8076, and qPitt 0.6847, 95% CI 0.5671–0.8023; P > 0.05 all pairwise comparisons]. All scores showed adequate calibration and precision. When dichotomized at the optimal cut-points of 11, 3, and 2 for the ICS, PBS, and qPitt, respectively, all scores had NPV > 90% at the expense of low PPV. Patients in the high-risk groups had a relative risk for mortality of 3.184 (95% CI 1.35–8.930), 3.068 (95% CI 1.094–8.606), and 2.850 (95% CI 1.016–7.994) for the dichotomized ICS, PBS, and qPitt, scores respectively. Treatment-related variables (early active antibiotic therapy, combination antibiotics and renal ceftazidime–avibactam dose adjustment) were not associated with mortality after controlling for the risk scores. Conclusions In patients treated with ceftazidime–avibactam for CRE infections, mortality risk scores demonstrated variable performance. Modifications to scoring systems to more accurately predict outcomes in the era of novel antibiotics are warranted

Speech delays and behavioral problems are the predominant features in individuals with developmental delays and 16p11.2 microdeletions and microduplications

Microdeletions and microduplications encompassing a ~593-kb region of 16p11.2 have been implicated as one of the most common genetic causes of susceptibility to autism/autism spectrum disorder (ASD). We report 45 microdeletions and 32 microduplications of 16p11.2, representing 0.78% of 9,773 individuals referred to our laboratory for microarray-based comparative genomic hybridization (aCGH) testing for neurodevelopmental and congenital anomalies. The microdeletion was de novo in 17 individuals and maternally inherited in five individuals for whom parental testing was available. Detailed histories of 18 individuals with 16p11.2 microdeletions were reviewed; all had developmental delays with below-average intelligence, and a majority had speech or language problems or delays and various behavioral problems. Of the 16 individuals old enough to be evaluated for autism, the speech/behavior profiles of seven did not suggest the need for ASD evaluation. Of the remaining nine individuals who had speech/behavior profiles that aroused clinical suspicion of ASD, five had formal evaluations, and three had PDD-NOS. Of the 19 microduplications with parental testing, five were de novo, nine were maternally inherited, and five were paternally inherited. A majority with the microduplication had delayed development and/or specific deficits in speech or language, though these features were not as consistent as seen with the microdeletions. This study, which is the largest cohort of individuals with 16p11.2 alterations reported to date, suggests that 16p11.2 microdeletions and microduplications are associated with a high frequency of cognitive, developmental, and speech delay and behavior abnormalities. Furthermore, although features associated with these alterations can be found in individuals with ASD, additional factors are likely required to lead to the development of ASD

Identification and quantification of dust aerosol emission over the Sahara from Cloud-Aerosol Lidar with Orthogonal Polarization (CALIOP) observations

Dust aerosols are an important component of the climate system and a challenge to incorporate into weather and climate models. Information on the location and magnitude of dust emission remains a key information gap to inform model development. Inadequate surface observations ensure that satellite data remain the primary source of this information over extensive and remote desert regions. Here, we develop estimates of the relative magnitude of active dust emission over the Sahara desert based on data from the Cloud-Aerosol Lidar with Orthogonal Polarization (CALIOP). Utilising the unique vertical profile of aerosol characteristics provided by CALIOP our algorithm identifies emission from aerosol extinction and lidar backscatter in the near surface layers. From the long-term CALIOP archive of day and night-time orbits over 2006–13 we construct coarse resolution maps of a new dust emission index (DEI) for the Sahara desert during the peak summer dust season (June to September). The spatial structure of DEI indicates highest emission over a broad zone focused on the border regions of Southern Algeria, Northern Mali and northwest Niger, displaced substantially (∼7°) to the east of the mean maximum in satellite-derived aerosol optical depth. In this region night-time emission exceeds that during the day. The DEI maps substantially corroborate recently derived dust source frequency count maps based on back-tracking plumes in high temporal resolution SEVIRI imagery. As such, a convergence of evidence from multiple satellite data sources using independent methods provides an increasingly robust picture of Saharan dust emission sources. Various caveats are considered. As such, quantitative estimates of dust emission may require a synergistic combined multi-sensor analysis

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

The available prognostic models for overall survival (OS) in patients with metastatic urothelial carcinoma (UC) have been derived from clinical trial populations of cisplatin-treated patients

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy

The Many Faces of Fear: Comparing the Pathways and Impacts of Nonconsumptive Predator Effects on Prey Populations

Background: Most ecological models assume that predator and prey populations interact solely through consumption: predators reduce prey densities by killing and consuming individual prey. However, predators can also reduce prey densities by forcing prey to adopt costly defensive strategies. Methodology/Principal Findings: We build on a simple Lotka-Volterra predator-prey model to provide a heuristic tool for distinguishing between the demographic effects of consumption (consumptive effects) and of anti-predator defenses (nonconsumptive effects), and for distinguishing among the multiple mechanisms by which anti-predator defenses might reduce prey population growth rates. We illustrate these alternative pathways for nonconsumptive effects with selected empirical examples, and use a meta-analysis of published literature to estimate the mean effect size of each pathway. Overall, predation risk tends to have a much larger impact on prey foraging behavior than measures of growth, survivorship, or fecundity. Conclusions/Significance: While our model provides a concise framework for understanding the many potential NCE pathways and their relationships to each other, our results confirm empirical research showing that prey are able to partially compensate for changes in energy income, mitigating the fitness effects of defensive changes in time budgets. Distinguishing the many facets of nonconsumptive effects raises some novel questions, and will help guide both empirica

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

Comment in Lowering the High Cost of Cancer Drugs--III. [Mayo Clin Proc. 2016] Lowering the High Cost of Cancer Drugs--I. [Mayo Clin Proc. 2016] Lowering the High Cost of Cancer Drugs--IV. [Mayo Clin Proc. 2016] In Reply--Lowering the High Cost of Cancer Drugs. [Mayo Clin Proc. 2016] US oncologists call for government regulation to curb drug price rises. [BMJ. 2015